Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia

@article{Lam2016HomoharringtonineM,
  title={Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia},
  author={Stephen Sze-Yuen Lam and Eric S. K. Ho and Bai-Liang He and Wui-Wing Wong and Chung-Ho Cher and Nelson Ka Lam Ng and Cheuk-him Man and Harinder Gill and Alice M. S. Cheung and Ho-Wan Ip and Chi-chiu So and Jerome Tamburini and Chi Wai Eric So and Dona N. Ho and Chun-Hang Au and Tsun-Leung Chan and Edmond Shiu-kwan Ma and Raymond Liang and Yok-Lam Kwong and Anskar Y. H. Leung},
  journal={Science Translational Medicine},
  year={2016},
  volume={8},
  pages={359ra129-359ra129}
}
An in vitro drug-screening platform on patient samples was developed and validated to design personalized treatment for relapsed/refractory acute myeloid leukemia (AML). Unbiased clustering and correlation showed that homoharringtonine (HHT), also known as omacetaxine mepesuccinate, exhibited preferential antileukemia effect against AML carrying internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD). It worked synergistically with FLT3 inhibitors to suppress leukemia growth in… CONTINUE READING
10
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

How Ribosomes Translate Cancer.

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The new perspectives of targeted therapy in acute myeloid leukemia.

  • Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Vardiman, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

D. A. Arber, A. Orazi, +5 authors J.W.M. Cazzola
  • Blood 127,
  • 2016
VIEW 1 EXCERPT

Acute Myeloid Leukemia.

  • The New England journal of medicine
  • 2015
VIEW 1 EXCERPT